Legal or Not: The DEA’s Ruling on CBD
Bethan Jenkins
October 11th, 2017
Policy
Is the Drug Enforcement Administration (DEA) cracking down on medical cannabis products? According to the latest reports, it seems that the news might not be a myth after all. The 2013 Farm Bill saw CBD products with a THC level of 0.3% or less become legal. Even President Obama was on board with the idea, until the DEA decided they wanted to change the legalities associated with products derived from the marijuana plant’s naturally-occurring compound, cannabidiol (CBD).
Sounds pretty crazy, right? Especially considering the fact that the Controlled Substances Act (CSA) released a statement clarifying the following:
“Oil made from cannabis seeds is on the list of exceptions to the illegality of ‘marihuana’. CBD oil extracted from hemp plants grown in Northern Europe is legal because hemp oil has been a legal import to the United States for decades.”
Nevertheless, the DEA told The Cannabist that cannabis extracts are ‘’federally illegal, Schedule I substances’. This means that the incredible growth we’ve seen in the marketing and selling of marijuana-derived concentrates are at risk of being removed from the shelves at marijuana dispensaries across the nation.
How can this be so, if CBD is a non-psychoactive compound, you ask? Well, the fight for federally legal cannabis extracts continues. Nonetheless, science has exposed the medical potential of CBD, from its ability to reduce seizures to the skin enhancement, anti-inflammatory and effects. With that being said (and so many cannabis advocates disagreeing with the DEA’s decision), a hemp war could be on the verge of erupting.
DEA’s Rule on CBD is Affecting the Economy and Consumers
If you’re a regular user of CBD-rich extracts, like oils and tinctures, not to worry. It’s not CBD users who are breaking the law, but the DEA. If this compound of the marijuana plant can cure ailments, diseases and widespread medical conditions, what’s the problem?
An economical impact is sure to be felt if the DEA’s decision sticks. The rule was put into place back on December 14, 2016. Known as the Final Rule establishing a new “Controlled Substance Code Number (drug code) for marijuana extract” outlines how CBD products are legal, if they are sourced from the part of the plant that is legal.
The Hemp Business Journal and Vote Hemp released astonishing figures of hemp sales throughout 2016, which surpassed $688 million. The DEA’s main targets are producers of products containing non-psychoactive cannabinoids. Since CBD is essentially a type of superfoods, there is no wonder why so many hemp supporters are unhappy with the ruling.
Hemp Industry Association Sues the DEA for CBD Ruling
At the end of September, well-known online store Target removed Charlotte’s Web CBD oil from their website. This was a shocker for CBD consumers, not to mention the producers of the oil, which was produced by the Stanley Brothers to cure a young girl named Charlotte Figi of serious epilepsy. The unexpected move by Target is expected to be linked to the DEA’s warning under the Controlled Substances Act.
For the people reading this, get ready to witness a forthcoming challenge, because the DEA is contesting the hemp industry’s claims. An argument from the Hemp Industries Association (HIA) highlights the following very relevant fact:
“The hemp industry had no right to challenge ‘marijuana extract’ rule. The DEA abused its authority because it failed to follow the appropriate procedures in scheduling marijuana extract and cannabinoids, as required by the Controlled Substances Act (CSA).”
Is the DEA leader or President Trump to blame for these hemp wars?
All of you pot lovers out there better be prepared for some changes in pot politics, because President Donald Trump is next in line to take on Chuck Rosenberg duties. Following two years of actively working as the best anti-drug official in the nation, Rosenberg will take a step back from the Drug Enforcement Administration and allow Trump to take the reigns.
Good or bad idea? Well, marijuana’s medical utility and its potential ‘dangers’ are two of many roles taken on by the DEA. If Trump can accomplish the task of reforming the laws on CBD oil, cannabis supporters will soon be able to relax. In the meantime, they wait anxiously, with the Marijuana Policy Project‘s communications director and American rights activist, Mason Tvert, saying:
“Our nation cannot afford another DEA administrator who refuses to differentiate between marijuana and heroin.”
Could there be a lawsuit to reverse the DEA’s decision?
Panic is being felt in the cannabis industry ever since the DEA announced that marijuana-based derivatives (CBD oil being a main one) would be classified as a Controlled Substance Code Number, Centuria Natural Foods, among many other pro-cannabis companies, have protested against the “Establishment of New Drug Code for Marihuana Extract”.
The DEA is being pretty stubborn. Conversely (and thankfully), the lawsuit does not agree with the DEA. Marijuana users can legally utilize the plant’s mature stalk and until the DEA is able to unearth any mind blowing new research pertaining to medicinal marijuana studies, you can relax a little. Vape that CBD-rich oil, extract your seeds and make some cannabutter; just stay updated with the DEA’s CBD laws!
For more information, sign up to our newsletter on the right.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Bethan Jenkins
Bethan is a full-time wanderluster, traveler, and digital nomad with 7 years of experience in the freelance writing world. She has mastered the art of beating jet lag and using hammocks as an office for content curation.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
Chemesis International is a vertically integrated global leader in the cannabis industry, currently operating within Puerto Rico, and California.
CB Therapeutics, Inc. is a biotechnology company focusing on the innovative production of high value molecules, compounds and rare ingredients from simple feedstock utilizing many different types of hosts and systems, including yeast, bacteria and cell-free expression systems.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
